RECRUITING

Smartphones for Opiate Addiction Recovery

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Treatments for opioid addiction exist, but effectiveness is compromised when subjects use illicit opiates during treatment. Reuse rates during treatment can be high, and reducing illicit opiate use during treatment has thus recently become a major NIDA policy goal. The 5-minute battery indicates the numerical probability that a patient will reuse illicit opiates within the next 7-10 days.

Official Title

Smartphones for Opiate Addiction Recovery

Quick Facts

Study Start:2021-11-01

Study Completion:2026-01-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05033028

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Meet DSM-5 criteria for opioid-use disorder (heroin and/or prescription opioids); * Have entered, or expressed a clear intention to enter, an OUD treatment program that prescribes either methadone or buprenorphine * Any gender; * 18 years of age and older; * Have used opioids other than as specifically prescribed within thirty days prior to consent; * In good-enough general health; * Capacity to provide written informed consent as assessed by our Subject Comprehension Assessment Tool(subjects lacking the ability to consent will not be enrolled) ; * Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study. * Licensed MD employed by the respective site, or at a clinical partner of the respective site, where they will act as participants and be part of the treatment team * Currently practicing in the treatment of OUD with either Buprenorphine or Methadone; * Able to speak, read, and write English fluently and to provide informed consent in English * Licensed MSW, NP, or MD; who are not part of any treatment team within the study and may be employees of their respective sites or other treatment facilities. * Currently practicing in the treatment of OUD with either Buprenorphine or Methadone; * Able to speak, read, and write English fluently and to provide informed consent in English	* Serious medical, psychiatric or non-opioid substance use disorder that, in the opinion of a study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments; * Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as assessed by history and/or clinical interview; * Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative detoxifications may be included); * Suicidal or homicidal ideation that requires immediate attention; * Presence of pain of sufficient severity as to require ongoing pain management with opioids; * Pending legal action or other reasons that might prevent an individual from completing the study. * Pregnancy as assessed by urine pregnancy testing * Breastfeeding of infants, as assessed by self-report. * Prisoners, as defined by OHRP, are excluded from participation in the study. * Individuals receiving residential court-ordered substance abuse treatment. * none * none

Inclusion Criteria

Exclusion Criteria

* Meet DSM-5 criteria for opioid-use disorder (heroin and/or prescription opioids);
* Have entered, or expressed a clear intention to enter, an OUD treatment program that prescribes either methadone or buprenorphine
* Any gender;
* 18 years of age and older;
* Have used opioids other than as specifically prescribed within thirty days prior to consent;
* In good-enough general health;
* Capacity to provide written informed consent as assessed by our Subject Comprehension Assessment Tool(subjects lacking the ability to consent will not be enrolled) ;
* Able to speak English sufficiently to understand the study procedures and provide written informed consent to participate in the study.
* Licensed MD employed by the respective site, or at a clinical partner of the respective site, where they will act as participants and be part of the treatment team
* Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
* Able to speak, read, and write English fluently and to provide informed consent in English
* Licensed MSW, NP, or MD; who are not part of any treatment team within the study and may be employees of their respective sites or other treatment facilities.
* Currently practicing in the treatment of OUD with either Buprenorphine or Methadone;
* Able to speak, read, and write English fluently and to provide informed consent in English

* Serious medical, psychiatric or non-opioid substance use disorder that, in the opinion of a study physician, would make study participation hazardous to the participant or compromise study findings or would prevent the participant from completing the study. Examples include: (a) Disabling or terminal medical illness (e.g., uncompensated heart failure, cirrhosis or end-stage liver disease) as assessed by medical history, review of systems, physical exam and/or laboratory assessments;
* Severe, untreated or inadequately treated mental disorder (e.g., active psychosis, uncontrolled manic-depressive illness) as assessed by history and/or clinical interview;
* Current severe alcohol, benzodiazepine, or other depressant or sedative hypnotic use likely to require a complicated medical detoxification (routine alcohol and sedative detoxifications may be included);
* Suicidal or homicidal ideation that requires immediate attention;
* Presence of pain of sufficient severity as to require ongoing pain management with opioids;
* Pending legal action or other reasons that might prevent an individual from completing the study.
* Pregnancy as assessed by urine pregnancy testing
* Breastfeeding of infants, as assessed by self-report.
* Prisoners, as defined by OHRP, are excluded from participation in the study.
* Individuals receiving residential court-ordered substance abuse treatment.
* none
* none

Contacts and Locations

Study Contact

Paul Glimcher

CONTACT

212-263-8167

Paul.glimcher@nyulangone.org

Principal Investigator

John Rotrosen, MD

PRINCIPAL_INVESTIGATOR

NYU Langone Health

Study Locations (Sites)

Rutgers University

Piscataway, New Jersey, 08854

United States

NYU Langone

New York, New York, 10016

United States

Collaborators and Investigators

Sponsor: NYU Langone Health

John Rotrosen, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-11-01

Study Completion Date2026-01-31

Study Record Updates

Study Start Date2021-11-01

Study Completion Date2026-01-31

Terms related to this study

Additional Relevant MeSH Terms

Opioid-use Disorder